TrialOncotarget2015

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.

Jack P Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.